EcoDrugPlus

Tyrosine-Protein Kinase Srk2-Like

Ensembl ID : ENSSTUG00000024032
Gene Symbol: LOC115198383
2 Cross references
188 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Tie-1-Like

Ensembl ID : ENSSTUG00000005979
Gene Symbol: LOC115192211
3 Cross references
200 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Tie-1-Like

Ensembl ID : ENSSTUG00000045449
Gene Symbol: LOC115158746
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Tie-2-Like

Ensembl ID : ENSSTUG00000018785
Gene Symbol: LOC115149540
3 Cross references
159 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Tie-2-Like

Ensembl ID : ENSSTUG00000017124
Gene Symbol: LOC115160173
3 Cross references
156 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSSTUG00000002413
Gene Symbol: LOC115154757
2 Cross references
184 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSSTUG00000041039
Gene Symbol: LOC115202631
2 Cross references
184 Possible Orthologues:

Tyrosine-Protein Phosphatase Non-Receptor Type 11

Ensembl ID : ENSSTUG00000015715
Gene Symbol: LOC115149292
3 Cross references
245 Possible Orthologues:

Tyrosine-Protein Phosphatase Non-Receptor Type 11-Like

Ensembl ID : ENSSTUG00000024087
Gene Symbol: LOC115159262
3 Cross references
245 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSSTUG00000003742
Gene Symbol: LOC115169781
3 Cross references
295 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSSTUG00000034327
Gene Symbol: LOC115204289
3 Cross references
20 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSSTUG00000026106
Gene Symbol: LOC115174513
3 Cross references
295 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).